

# CITATION REPORT

List of articles citing

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

DOI: 10.1002/hep.510280241  
Hepatology, 1998, 28, 585-9.

**Source:** <https://exaly.com/paper-pdf/29004259/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
448	Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. <b>1999</b> , 17, 394-8		147
447	Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection?. <b>1999</b> , 45, 475-6		6
446	Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. <b>1999</b> , 45, 306-9		38
445	Screening for hepatocellular carcinoma. <b>1999</b> , 13, 623-35		21
444	Treatment of chronic hepatitis B: new antiviral therapies. <b>1999</b> , 1, 20-6		4
443	Hepatitis B. <b>1999</b> , 2, 463-472		
442	Summary of the first international symposium on viral hepatitis. <b>1999</b> , 42, 77-96		3
441	Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. <b>1999</b> , 5, 512-9		93
440	Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. <b>1999</b> , 5, 520-5		112
439	Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. <b>1999</b> , 5, 491-6		123
438	Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. <b>1999</b> , 59, 263-9		68
437	Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. <b>1999</b> , 59, 270-276		75
436	A pill a day, or two, for hepatitis B?. <b>1999</b> , 353, 1032-3		15
435	High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. <b>1999</b> , 30, 715-21		134
434	Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. <b>1999</b> , 31, 2461-3		0
433	THERAPY WITH NUCLEOSIDE ANALOGUES FOR HEPATITIS B VIRUS INFECTION. <b>1999</b> , 3, 349-361		15
432	HEPATITIS B VIRUS AND LIVER TRANSPLANTATION. <b>1999</b> , 3, 389-415		17

431	Lamivudine. A review of its therapeutic potential in chronic hepatitis B. <b>1999</b> , 58, 101-41		106
430	Antiviral agents for non-human immunodeficiency virus infections. <b>1999</b> , 74, 1266-83		26
429	Bibliography current world literature. <i>Current Opinion in Gastroenterology</i> , <b>2000</b> , 16, B1-55	3	
428	Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. <i>Transplantation</i> , <b>2000</b> , 70, 809-15	1.8	127
427	End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. <b>2000</b> , 61, 403-8		20
426	Right lobe living donor liver transplantation: a review. <b>2000</b> , 6, 3-20		173
425	Liver transplantation. American Association for the Study of Liver Diseases. <b>2000</b> , 6, 122-35		83
424	Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. <b>2000</b> , 15, 227-9		2
423	Antibodies for the prevention and treatment of viral diseases. <b>2000</b> , 47, 57-77		113
422	Liver transplantation of patients in end-stage cirrhosis. <b>2000</b> , 14, 1049-73		9
421	Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. <i>Hepatology</i> , <b>2000</b> , 32, 1189-95	11.2	199
420	Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. <i>Hepatology</i> , <b>2000</b> , 32, 588-96	11.2	69
419	Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. <b>2000</b> , 6, 715-20		28
418	An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. <b>2000</b> , 6, 741-8		189
417	Posttransplantation prevention and treatment of recurrent hepatitis B. <b>2000</b> , 6, S47-51		12
416	Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. <b>2000</b> , 6, 429-33		200
415	Acute Viral Hepatitis. <b>2000</b> , 3, 481-486		8
414	[Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]. <b>2000</b> , 38, 773-83		8

413	Hepatitis B and C in the liver transplant recipient. <b>2000</b> , 20, 465-80	13
412	Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. <b>2000</b> , 181, 2063-6	55
411	Hepatitis C virus RNA-dependent RNA polymerase (NS5B polymerase). <b>2000</b> , 242, 225-60	26
410	Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. <b>2000</b> , 74, 10407-16	160
409	Hepatitis B in transplantation. <b>2000</b> , 2, 153-65	9
408	Liver transplantation in Chinese patients with chronic hepatitis B. <b>2000</b> , 32, 2162-3	2
407	Adult-to-adult living-related liver transplantation for hepatitis B-related cirrhosis in Japan: two case reports. <b>2000</b> , 32, 2189-92	0
406	Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. <b>2000</b> , 32, 2245-7	17
405	Recurrent hepatitis B, hepatitis C, and combined hepatitis B and C in liver allografts: a comparative pathological study. <b>2000</b> , 31, 101-8	18
404	Prevention of recurrence of hepatitis B virus infection after liver transplantation. <b>2000</b> , 13, 189-94	3
403	Monotherapy Versus Combination Therapy in the Prevention of Hepatitis B in Liver Transplant Recipients. <b>2000</b> , 14, 205-209	
402	Chronic rejection of the liver: the role of immunosuppression. <b>2000</b> , 14, 283-97	4
401	Viral hepatitis A, B, and C. <b>2000</b> , 4, 47-71, vi	9
400	Viral hepatitis in the liver transplant recipient. <b>2000</b> , 14, 761-84	24
399	Disease recurrence following liver transplantation. <b>2000</b> , 4, 675-89, ix-x	13
398	Right lobe living donor liver transplantation: A review. <b>2000</b> , 6, 3-20	133
397	Liver transplantation. <b>2000</b> , 6, 122-135	3
396	Hepatology in the new millennium. Advances in viral hepatitis, hepatic disorders, and liver transplantation. <b>2000</b> , 84, 1085-105	4

395	Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. <b>2000</b> , 119, 1382-4	53
394	Combination chemotherapy for hepatitis B virus: the path forward?. <b>2000</b> , 60, 517-31	27
393	Antiviral chemotherapy for the treatment of hepatitis B virus infections. <b>2000</b> , 118, S83-103	92
392	Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. <b>2000</b> , 32, 300-6	207
391	Successful orthotopic liver transplantation. <b>2001</b> , 120, 1561-2	2
390	Lamivudine resistance in hepatitis B: mechanisms and clinical implications. <b>2001</b> , 4, 118-28	51
389	Reply. <b>2001</b> , 120, 1561-1562	
388	Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. <b>2001</b> , 34, 888-94	121
387	Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. <b>2001</b> , 34, 903-10	187
386	Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. <b>2001</b> , 34, 895-902	169
385	Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. <b>2001</b> , 34, 943-5	20
384	Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus. <b>2001</b> , 35, 679-81	33
383	A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. <b>2001</b> , 7, 504-10	51
382	Advances in pre- and posttransplant management of hepatitis B virus. <b>2001</b> , 33, 1315-6	
381	Pre-liver transplant viremic status and the choice of anti-HBV regimens. <b>2001</b> , 33, 1428-9	1
380	Reduced doses of hepatitis B immunoglobulin protect against hepatitis B virus infection recurrence after liver transplantation. <b>2001</b> , 33, 2551-3	8
379	Recurrent disease after liver transplantation. <b>2001</b> , 33, 2716-9	2
378	Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation. <b>2001</b> , 33, 3637-8	13

377	Modifications of immunosuppression in hepatitis B virus infection. <b>2001</b> , 6, 331-337		3
376	Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. <b>2001</b> , 233, 276-81		110
375	Hepatitis in the organ transplant patient. <b>2001</b> , 6, 295-300		2
374	Liver transplantation. <i>Current Opinion in Gastroenterology</i> , <b>2001</b> , 17, 299-303	3	1
373	Chronic Hepatitis B. <b>2001</b> , 4, 493-502		1
372	Stellenwert der Lebertransplantation beim hepatozellulären Karzinom. <b>2001</b> , 7, 1296-1304		
371	Living-related partial liver transplantation for decompensated hepatitis B without reactivation of hepatitis B in the following 30 months. <b>2001</b> , 36, 637-42		2
370	A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , <b>2001</b> , 33, 424-32	11.2	330
369	Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients. <i>Hepatology</i> , <b>2001</b> , 34, 126-32	11.2	19
368	Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. <b>2001</b> , 7, 513-7		84
367	Lamivudine for hepatitis B after liver transplantation. <b>2001</b> , 7, 511-2		3
366	Outcome of liver transplantation for hepatitis B: report of a single center's experience. <b>2001</b> , 7, 724-31		13
365	Analysis of causes of death in liver transplant recipients who survived more than 3 years. <b>2001</b> , 7, 811-5		227
364	Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. <b>2001</b> , 7, 976-82		31
363	Posttransplantation care: role of the primary care physician versus transplant center. <b>2001</b> , 7, S2-12		27
362	Hepatitis B and C in the liver transplant recipient: current understanding and treatment. <b>2001</b> , 7, S87-98		26
361	Late hepatic allograft dysfunction. <b>2001</b> , 7, S60-73		31
360	Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. <b>2001</b> , 49, 75-81		56

359	Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. <b>2001</b> , 15 Suppl 6, 55-8	30
358	A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. <b>2001</b> , 1, 51-4	8
357	Approach to the Management of Allograft Recipients Following the Detection of Hepatitis B Virus in the Prospective Organ Donor. <b>2001</b> , 1, 185-191	71
356	Histologic recurrence-free outcome after orthotopic liver transplantation for chronic hepatitis B. <b>2001</b> , 9, 19-28	
355	Update on chronic viral hepatitis. <b>2001</b> , 77, 498-505	18
354	Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. <b>2001</b> , 49, 860-3	51
353	Current treatment strategies for chronic hepatitis B and C. <b>2001</b> , 52, 29-49	56
352	Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. <b>2001</b> , 49, 436-40	70
351	Prevention of fungal and hepatitis virus infections in liver transplantation. <b>2001</b> , 33 Suppl 1, S47-52	46
350	Infection in the Organ Transplant Recipient. <b>2002</b> , 573-679	26
349	Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. <b>2002</b> , 40, 795-9	15
348	New era of liver transplantation for hepatitis B: a 17-year single-center experience. <b>2002</b> , 235, 611-9; discussion 619-20	87
347	A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection. <b>2002</b> , 25, 497-510	19
346	Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. <b>2002</b> , 97, 1618-28	99
345	Immunisations in solid-organ transplant recipients. <b>2002</b> , 359, 957-65	54
344	Is lamivudine with 1-week HBIg as effective as long-term high-dose HBIg in HBV prophylaxis after liver transplantation?. <b>2002</b> , 34, 1252-4	21
343	Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. <b>2002</b> , 34, 2285-7	4
342	The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. <b>2002</b> , 25, 97-106	149

341	Factors associated with viral breakthrough in lamivudine monophylaxis of hepatitis B virus recurrence after liver transplantation. <b>2002</b> , 68, 182-7		79
340	Treatment of hepatitis B and C following liver transplantation. <b>2002</b> , 4, 52-62		2
339	Evolving experience of hepatitis B virus prophylaxis in liver transplantation. <b>2002</b> , 4, 137-43		26
338	Management of viral hepatitis B. <b>2002</b> , 17 Suppl, S125-45		55
337	Disease recurrence after liver transplantation: need we worry?. <b>2002</b> , 17, 733-6		2
336	Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. <b>2002</b> , 299, 88-99		124
335	Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. <i>Hepatology</i> , <b>2002</b> , 35, 673-9	11.2	59
334	Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. <i>Hepatology</i> , <b>2002</b> , 35, 1528-35	11.2	160
333	A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. <b>2002</b> , 8, 2-9		28
332	Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. <b>2002</b> , 8, 433-9		102
331	Safe use of livers from donors with positive hepatitis B core antibody. <b>2002</b> , 8, 556-61		74
330	Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype. <b>2002</b> , 8, 550-5		26
329	Hepatitis B: progress in the last 15 years. <b>2002</b> , 8, S59-66		18
328	Treatment of recurrent hepatitis C. <b>2002</b> , 8, S28-37		39
327	Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , <b>2003</b> , 37, 36-43	11.2	59
326	Adoptive transfer of immunity to HBV through liver graft: does it prevent HBV recurrence?. <i>Hepatology</i> , <b>2003</b> , 37, 16-8	11.2	2
325	HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. <i>Hepatology</i> , <b>2003</b> , 38, 86-95	11.2	180
324	Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. <b>2003</b> , 9, 182-7		62



323	Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. <b>2003</b> , 9, 837-42		39
322	Treatment of hepatitis B and C following liver transplantation. <b>2003</b> , 2, 71-78		
321	Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. <b>2003</b> , 3, 250-8		59
320	Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. <b>2003</b> , 3, 999-1002		51
319	Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. <i>Hepatology</i> , <b>2003</b> , 38, 811-819	11.2	106
318	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. <b>2003</b> , 71, 367-75		32
317	Monoclonal antibody therapy for posttransplant lymphoproliferative disorders. <b>2000</b> , 6, 657-8		
316	HBV vaccination and liver transplantation for hepatitis B: winning by recruiting from within?. <b>2000</b> , 6, 659-61		1
315	Does OKT3 increase the risk of recurrent hepatitis B in patients transplanted for hepatitis B?. <b>2000</b> , 6, 810-2		
314	Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. <b>2003</b> , 17, 254-8		33
313	Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. <b>2003</b> , 253, 544-52		24
312	Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. <b>2003</b> , 7, 667-81		7
311	Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. <b>2003</b> , 7, 551-72		8
310	Recent advances in liver transplantation. <b>2003</b> , 78, 197-210		69
309	Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. <i>Hepatology</i> , <b>2003</b> , 38, 811-9	11.2	125
308	A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. <b>2003</b> , 38, 811-7		148
307	Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation?. <b>2003</b> , 38, 850-2		11
306	Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. <b>2003</b> , 35, 609-11		12

305	Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. <b>2003</b> , 35, 723-4		16
304	Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease. <b>2003</b> , 35, 1028-9		2
303	Use of combined treatment of hepatitis B immune globulin and lamivudine as prevention of hepatitis B virus recurrence in liver allograft. <b>2003</b> , 35, 1844-5		5
302	Liver transplantation in patients with HIV infection. <b>2003</b> , 39, 3-6		58
301	Management of the patient with hepatitis B virus-related cirrhosis. <b>2003</b> , 39 Suppl 1, S177-80		11
300	Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. <b>2003</b> , 39 Suppl 1, S181-9		31
299	Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. <b>2003</b> , 39, 466-74		30
298	Hepatitis B. <b>2003</b> , 10, 31-97		3
297	[Liver transplantation in Germany]. <b>2003</b> , 128, 831-41		4
296	Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. <b>2003</b> , 23, 125-36		104
295	Hepatitis B core antibody-positive grafts: recipient risk. <i>Transplantation</i> , <b>2003</b> , 75, S49-53	1.8	51
294	Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. <i>Transplantation</i> , <b>2003</b> , 76, 1174-9	1.8	54
293	Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. <i>Transplantation</i> , <b>2003</b> , 75, 1179-86	1.8	70
292	Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. <i>Transplantation</i> , <b>2003</b> , 75, S41-4	1.8	29
291	Transplanting solid organs from HBsAg negative donors positive for antibody to hepatitis B core antigen: the implications. <b>2003</b> , 26, 972-83		1
290	Steroid avoidance in liver transplantation. <b>2004</b> , 18 Suppl C, 5C-11C		1
289	Management of hepatitis B in liver transplantation patients. <b>2004</b> , 24 Suppl 1, 55-62		46
288	Atlas of the Liver. <b>2004</b> ,		

287	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprohylaxis. <b>2004</b> , 18, 295-300	31
286	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. <b>2004</b> , 17, 746-758	13
285	Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. <b>2004</b> , 58, 877-86	21
284	Transplantation and prevention of reinfection. <b>2004</b> , 3, 67-75	1
283	Post-transplant hepatitis: HCV and HBV. <b>2004</b> , 3, 98-104	1
282	Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. <b>2004</b> , 10, 58-64	46
281	Liver transplantation in patients with hepatocellular carcinoma. <b>2004</b> , 10, S81-5	32
280	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. <b>2004</b> , 10, 557-63	26
279	Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. <b>2004</b> , 10, 728-33	67
278	Evolving strategies to prevent HBV recurrence. <b>2004</b> , 10, S74-85	76
277	Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. <b>2004</b> , 10, 1372-8	70
276	Liver transplantation for hepatitis B. <b>2004</b> , 29, 193-201	12
275	Antiviral therapy in patients with chronic hepatitis B and cirrhosis. <b>2004</b> , 33, 629-54, x-xi	10
274	Current therapies for chronic hepatitis B virus infection. <b>2004</b> , 2, 745-60	8
273	Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. <b>2004</b> , 36, 535-8	44
272	Prevention of hepatitis B virus recurrence after living donor liver transplantation. <b>2004</b> , 36, 2764-7	5
271	Management of chronic hepatitis B in the liver transplant setting. <b>2004</b> , 18, 171-182	2
270	Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. <b>2004</b> , 41, 362-9	19

269	Hepatitis B and hepatitis C viruses in liver transplantation. <i>Transplantation</i> , <b>2004</b> , 78, 955-63	1.8	38
268	Advances in liver transplantation. New strategies and current care expand access, enhance survival. <b>2004</b> , 115, 73-6, 79-85		23
267	Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. <b>2005</b> , 241, 905-16; discussion 916-8		312
266	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. <b>2005</b> , 17, 746-58		5
265	Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. <b>2005</b> , 25, 1169-74		29
264	Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. <b>2005</b> , 19, 321-6		15
263	Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. <b>2005</b> , 20, 1527-32		16
262	HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. <b>2005</b> , 12, 212-5		30
261	[Prevention and treatment of hepatitis B virus infection after liver transplantation]. <b>2005</b> , 29, 393-404		
260	Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. <b>2005</b> , 11, 532-8		64
259	Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. <b>2005</b> , 11, 402-9		145
258	Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. <b>2005</b> , 11, 807-813		78
257	Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. <b>2005</b> , 11, 716-732		134
256	Management of HBV Infection in Liver Transplantation Patients. <b>2005</b> , 2, 41-49		18
255	The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B. <b>2005</b> , 42, 158-62		9
254	Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. <b>2005</b> , 43, 283-7		81
253	The questionable role of immunization against hepatitis B in HBV infected liver transplant patients. <b>2005</b> , 43, 203-6		6
252	Extended HBV vaccination in liver transplant recipients for HBV-related cirrhosis: report of two successful cases. <b>2005</b> , 37, 793-8		2

251	[Liver transplantation for complications of hepatitis B]. <b>2006</b> , 35, 335-45	
250	[Viral hepatitis infections in transplant recipients]. <b>2006</b> , 24, 118-28	
249	Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. <b>2006</b> , 38, 579-83	32
248	Hepatitis B: Where Are We Today?. <b>2006</b> , 33, 441-452	1
247	Lamivudine or adefovir dipivoxil for preventing hepatitis B recurrence after liver transplantation. <b>2006</b> ,	
246	Liver transplantation in HIV-infected patients. <b>2006</b> , 11, 608-612	1
245	Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. <b>2006</b> , 5, 8	30
244	Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. <b>2006</b> , 62, 511-2	10
243	[Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?]. <b>2006</b> , 101, 939-50	2
242	Management of recurrent viral hepatitis B and C after liver transplantation. <b>2006</b> , 8, 60-6	3
241	Prise en charge de la résistance à la lamivudine en transplantation hépatique pour hépatopathie B. <b>2006</b> , 30, 26-30	
240	Prevention of hepatitis B virus recurrence after liver transplantation. <b>2006</b> , 20 Suppl 17, 111-6	17
239	Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. <b>2006</b> , 12, 316-9	39
238	Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. <b>2006</b> , 12, 253-8	136
237	Established and emerging therapies for the treatment of viral hepatitis. <b>2006</b> , 24, 160-73	11
236	Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. <b>2006</b> , 101, 2076-89	67
235	Current treatment of hepatitis B. <b>2008</b> , 57, 105-24	19
234	Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. <b>2007</b> , 22 Suppl 8, viii37-viii46	14

233	[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. <b>2007</b> , 45, 525-74		32
232	Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. <b>2007</b> , 45, 1281-328		49
231	Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. <i>Transplantation</i> , <b>2007</b> , 83, 231-3	1.8	28
230	Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. <i>Transplantation</i> , <b>2007</b> , 84, 650-4	1.8	81
229	HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. <b>2007</b> , 46, 635-44		27
228	Hepatitis B and end-stage liver disease. <b>2007</b> , 11, 893-916, ix		13
227	Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. <b>2007</b> , 132, 931-7		224
226	Management of hepatitis B: summary of a clinical research workshop. <i>Hepatology</i> , <b>2007</b> , 45, 1056-75	11.2	473
225	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. <b>2007</b> , 13, 349-60		204
224	Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. <b>2007</b> , 13, 367-73		62
223	Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. <b>2007</b> , 13, 374-81		91
222	New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: what will be their impact on the prophylaxis of HBV infection?. <b>2007</b> , 13, 1084-7		3
221	Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. <b>2007</b> , 22, 2130-4		38
220	Management of hepatitis B in liver transplant recipients. <b>2007</b> , 14 Suppl 1, 37-44		47
219	Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. <b>2008</b> , 28, 72-8		18
218	Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. <b>2007</b> , 7, 434-9		51
217	[The prophylaxis against post-liver-transplant hepatitis B re-infection]. <b>2007</b> , 31, 30-7		
216	Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. <b>2007</b> , 52, 2497-500		50

215	[Current concepts for prophylaxis and treatment of hepatitis B virus reinfection after liver transplantation]. <b>2008</b> , 103, 190-7		2
214	Dual therapy for chronic hepatitis B virus. <b>2008</b> , 7, 33-39		
213	History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. <b>2008</b> , 1, 83-86		13
212	Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. <b>2008</b> , 80, 1891-9		20
211	Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?. <b>2008</b> , 14 Suppl 2, S15-22		33
210	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. <i>Hepatology</i> , <b>2008</b> , 48, 1460-6	11.2	133
209	Liver transplantation in viral hepatitis: prevention of recurrence. <b>2008</b> , 22, 1153-69		12
208	The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. <b>2008</b> , 21, 459-65		143
207	[Liver transplantation for chronic hepatitis B]. <b>2008</b> , 32, S25-33		4
206	Indications for liver transplantation. <b>2008</b> , 134, 1764-76		138
205	Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. <b>2008</b> , 134, 1890-9; quiz 2155		131
204	The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. <b>2008</b> , 41, 243-54		37
203	Erratum to RThe management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meetingR[J. Clin. Virol. 41 (4) 2008 243-254]. <b>2008</b> , 42, 104-15		28
202	Care of the liver transplant patient. <b>2008</b> , 54, 486-507		2
201	Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. <b>2008</b> , 2, 465-95		1
200	Hepatitis B immune globulin and HBV-related liver transplantation. <b>2008</b> , 8, 1815-22		2
199	Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. <i>Transplantation</i> , <b>2008</b> , 85, 1105-11	1.8	31
198	Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2489-99	5.6	17

197	Management of Hepatitis B in the peri-transplant period. <b>2009</b> , 6, 29		
196	Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. <b>2009</b> , 90, 115-26		17
195	Viral hepatitis in solid organ transplant recipients. <b>2009</b> , 9 Suppl 4, S116-30		43
194	Reactivation of hepatitis B. <i>Hepatology</i> , <b>2009</b> , 49, S156-65	11.2	396
193	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. <b>2009</b> , 81, 224-9		16
192	Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. <b>2009</b> , 15, 1525-34		69
191	Hepatitis-B- und -C-Reinfektion: Prophylaxe und Therapie. <b>2009</b> , 4, 526-539		
190	Hepatitis B and liver transplantation: 2008 update. <b>2009</b> , 19, 7-29		16
189	Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. <b>2009</b> , 22, 805-13		25
188	Current management of hepatitis B virus infection before and after liver transplantation. <b>2009</b> , 29, 1294-305		58
187	Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. <b>2009</b> , 15, 413-20		25
186	[Liver transplantation in patients with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus]. <b>2009</b> , 38, 1281-9		7
185	The option of liver transplantation for hepatitis B: where are we?. <b>2009</b> , 41 Suppl 2, S185-9		10
184	Hepatitis B immunoglobulin in preventing reinfection following liver transplantation. <b>2009</b> , 7, 321-8		2
183	Liver Transplantation. <b>2009</b> ,		1
182	Prevention of HBV recurrence after liver transplant: The role of combination therapy. <b>2009</b> , 3, 98-103		
181	Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. <i>Transplantation</i> , <b>2009</b> , 87, 103-11	1.8	30
180	The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation. <b>2009</b> , 48, 1577-83		2



179	Hepatitis B and Liver Transplantation. <b>2009</b> , 4, 194-201	
178	Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. <b>2009</b> , 14, 225-30	17
177	Deceased donor liver transplantation. <i>Acta Hepatologica Japonica</i> , <b>2010</b> , 51, 143-162	0.3
176	[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. <b>2010</b> , 122, 280-302	2
175	Posttransplant prophylaxis strategies for hepatitis B. <b>2010</b> , 10, 1721-2	2
174	Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. <b>2010</b> , 10, 1861-9	73
173	Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose?1. <b>2010</b> , 16, S36-S39	3
172	Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. <b>2010</b> , 10, 71	6
171	One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. <b>2010</b> , 23, 1105-12	33
170	Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. <b>2010</b> , 12, 292-308	79
169	Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. <b>2010</b> , CD006005	13
168	Managing HBV in patients with impaired immunity. <b>2010</b> , 59, 1430-45	54
167	Management of end-stage liver disease in chronic hepatitis B. <b>2010</b> , 14, 477-93	3
166	Antiviral drug resistance: mechanisms and clinical implications. <b>2010</b> , 24, 809-33	48
165	Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. <b>2010</b> , 42, 509-14	9
164	Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. <b>2010</b> , 42, 578-84	29
163	Antiviral drug resistance: mechanisms and clinical implications. <b>2010</b> , 24, 413-37	85
162	Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. <b>2011</b> , 141, 1212-9	169

161	Current status of liver transplantation for hepatitis B virus. <b>2011</b> , 15, 753-64	13
160	Passive immunization. <b>2011</b> , 38, 681-91, viii	7
159	HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. <b>2011</b> , 43 Suppl 1, S49-56	17
158	Management of viral infections in solid organ transplant recipients. <b>2011</b> , 9, 685-700	17
157	Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. <b>2011</b> , 7, 429-36	9
156	Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. <b>2011</b> , 55, 587-593	68
155	Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients. <b>2011</b> , 41, 1189-98	3
154	Management of hepatitis B virus infection in the pre-transplant setting. <b>2011</b> , 5, 10-14	
153	Optimization of hepatitis B virus prophylaxis after liver transplantation. <b>2011</b> , 5, 15-18	
152	Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?. <b>2011</b> , 10, 180-187	17
151	Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. <b>2011</b> , 25, 517-22	12
150	Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. <b>2011</b> , 13, 299-302	11
149	Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. <b>2011</b> , 46, 367-77	21
148	Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. <b>2011</b> , 5, 918-926	25
147	Prevention of post liver transplant HBV recurrence. <b>2011</b> , 5, 876-81	3
146	Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. <b>2011</b> , 17, 1176-90	96
145	[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. <b>2011</b> , 49, 871-930	121
144	Republished paper: Managing HBV in patients with impaired immunity. <b>2011</b> , 87, 223-38	2

143	Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 638-45	1.8	9
142	Hepatitis B immune globulin in liver transplantation prophylaxis: an update. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 168-76	1.8	10
141	Recurrent Viral Diseases after Liver Transplantation. <b>2012</b> , 883-909		
140	Liver transplantation in delta virus infection. <b>2012</b> , 32, 245-55		35
139	The option of HBIG-free prophylaxis against recurrent HBV. <b>2012</b> , 56, 1189-1197		61
138	The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. <b>2012</b> , 26, E561-9		16
137	Viral hepatitis in liver transplantation. <b>2012</b> , 142, 1373-1383.e1		156
136	Chronic hepatitis B infection. <b>2012</b> , 16, 347-69		44
135	Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. <b>2012</b> , 7, e32189		6
134	Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update. <b>2012</b> , 11, 102-110		
133	The role of HBIG as hepatitis B reinfection prophylaxis following liver transplantation. <b>2012</b> , 397, 697-710		7
132	Viral hepatitis in solid organ transplantation. <b>2013</b> , 13 Suppl 4, 147-68		64
131	Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?. <b>2013</b> , 48, 1373-83		15
130	Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. <b>2013</b> , 20, 3582-90		21
129	Adult-to-adult right-lobe living donor liver transplantation in recipients with hepatitis B virus-related benign liver disease and high model end-stage liver disease scores. <b>2013</b> , 43, 1039-48		13
128	Prevention of recurrent hepatitis B infection after liver transplantation. <b>2013</b> , 12, 465-72		11
127	Hepatitis B virus: Prevention of recurrent infection. <b>2013</b> , 2, 169-172		
126	Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. <b>2013</b> , 3, 301-12		17

125	The effect of pretransplantation lamivudine resistance on the prognosis of liver transplant recipients. <b>2013</b> , 45, 231-5		
124	Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. <b>2013</b> , 17, 451-73		13
123	Prophylaxis for recurrent hepatitis B virus infection following liver transplantation. <b>2013</b> , 43, 65-6		
122	High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. <b>2013</b> , 13, 353-62		104
121	Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study. <b>2013</b> , 13, 348-52		29
120	Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection. <b>2013</b> , 45, 1953-6		6
119	Current Management of HBV Pre and Post Liver Transplant. <b>2013</b> , 12, 119-123		
118	Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. <b>2013</b> , 108, 942-8		94
117	Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. <i>Hepatitis Monthly</i> , <b>2013</b> , 13, e6609	1.8	5
116	Prophylaxis of hepatitis B infection in solid organ transplant recipients. <b>2013</b> , 6, 309-19		13
115	Impact of recipient age and preoperative fasting blood glucose level as the risk factors of living donor liver transplantation in cirrhotic patients in the recent comprehensive era with knowledge of indications: Recent status in a Japanese single center. <b>2013</b> , 43, 1148-55		5
114	Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. <b>2013</b> , 28, 1217-22		33
113	Antiviral treatment for hepatitis B virus recurrence following liver transplantation. <b>2013</b> , 27, E597-604		9
112	Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. <b>2013</b> , 19, 268-74		75
111	Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. <i>Transplantation</i> , <b>2013</b> , 95, 755-60	1.8	197
110	Living donor liver transplantation for patients with alcoholic liver disease. <b>2013</b> , 17, 14-20		5
109	One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. <b>2014</b> , 28, 41-4		28
108	Contradictory immune response in post liver transplantation hepatitis B and C. <b>2014</b> , 2014, 814760		2

107	HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. <b>2016</b> , 35, 312-324		12
106	Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. <b>2014</b> , 29, 554-60		14
105	Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. <b>2014</b> , 20, 1211-20		20
104	Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease. <b>2014</b> , 2014, 764234		7
103	JSH Guidelines for the Management of Hepatitis B Virus Infection. <b>2014</b> , 44 Suppl S1, 1-58		120
102	Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. <b>2014</b> , 32, 5077-82		40
101	Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. <i>Transplantation</i> , <b>2014</b> , 97 Suppl 8, S53-9	1.8	25
100	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. <i>Transplantation</i> , <b>2015</b> , 99, 1321-34	1.8	45
99	Use of Extended Criteria Deceased Donors in Adult Liver Transplantation. <b>2015</b> , 3, 1		
98	Recent advances in prevention of hepatitis B recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 829-35	5.6	12
97	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <b>2015</b> , 35, 2187-93		2
96	Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 17-year experience at a single center. <b>2015</b> , 45, 1203-10		6
95	Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 8140-7	5.6	11
94	Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. <b>2015</b> , 16, 17494-513		7
93	Viral Hepatitis. <b>2015</b> , 1439-1468.e7		4
92	Management of chronic hepatitis B in patients from special populations. <b>2015</b> , 5,		2
91	Transplantation for Hepatitis A and B. <b>2015</b> , 105-119		
90	Outcomes of Living Donor Transplantation. <b>2015</b> , 754-759		

89	Therapy of Delta Hepatitis. <b>2015</b> , 5,	8
88	Safe and cost-effective control of post-transplantation recurrence of hepatitis B. <b>2015</b> , 45, 38-47	16
87	Antiviral Combination Therapy With Low-Dose Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Virus Recurrence in Liver Transplant Recipients: A Single-Center Experience. <b>2015</b> , 47, 1445-9	9
86	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2016</b> , 22, 18-75	6.9 141
85	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. <b>2016</b> , 22, 324-32	12
84	Liver transplantation and hepatitis B virus infection: towards an immunoglobulin-free antiviral treatment after transplantation. <b>2016</b> , 21, 219-23	3
83	New insights after the first 1000 liver transplantations at The University of Hong Kong. <b>2016</b> , 39, 202-10	11
82	Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative. <b>2016</b> , 15, 316-8	8
81	Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus. <b>2016</b> , 48, 2119-23	18
80	Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. <b>2016</b> , 46, 541-51	11
79	Discontinuation of Hepatitis B Immunoglobulin by Long-term Hepatitis B Vaccine Inoculation in Preventing Hepatitis B Recurrence After Liver Transplantation. <b>2016</b> , 48, 1179-83	3
78	EASL Clinical Practice Guidelines: Liver transplantation. <b>2016</b> , 64, 433-485	484
77	Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management. <b>2016</b> , 10, 106-14	2
76	Significance of anti-HBc alone serological status in clinical practice. <b>2017</b> , 2, 123-134	28
75	Recurrent Hepatitis B and D Virus Infection in a Liver Transplant Recipient. <b>2017</b> , 49, 175-177	5
74	Is hepatitis B immune globulin still needed after liver transplantation for chronic hepatitis B?. <i>Hepatology</i> , <b>2017</b> , 66, 1023-1025	11.2 5
73	Recurrent Disease Following Liver Transplantation. <b>2017</b> , 1127-1142	
72	The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. <b>2017</b> , 52, 366-375	7

71	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <b>2018</b> , 47, 43-54		105
70	Clinical outcome of 1,000 consecutive cases of liver transplantation: a single center experience. <b>2018</b> , 95, 267-277		7
69	Hepatitis B Vaccination in Patients Receiving Oral Antiviral Therapy Without Hepatitis B Immunoglobulin After Liver Transplant. <b>2018</b> , 50, 3681-3688		2
68	Pathology of Liver Transplantation. <b>2018</b> , 629-662		1
67	The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence. <b>2019</b> , 49, 1019-1024		2
66	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 93-159	6.9	87
65	Hepatitis B virus recurrence after living donor liver transplantation of anti-HBc-positive grafts: A 22-year experience at a single center. <b>2019</b> , 13, 448-455		7
64	Recurrence of Hepatitis D Virus in Liver Transplant Recipients With Hepatitis B and D Virus-Related Chronic Liver Disease. <b>2019</b> , 51, 2457-2460		9
63	Efficacy and safety of Niuliva <sup>®</sup> immune globulin to prevent hepatitis B reinfection in 'de novo' orthotopic liver transplant. <b>2019</b> , 14, 85-94		
62	Antiviral Therapy for AECHB and Severe Hepatitis B (Liver Failure). <b>2019</b> , 371-455		
61	Acute Exacerbation of Chronic Hepatitis B. <b>2019</b> ,		
60	Taiwan consensus statement on the management of chronic hepatitis B. <b>2019</b> , 118, 7-38		25
59	Biological Principles and Clinical Issues Underlying Liver Transplantation for Viral-Induced End-Stage Liver Disease in the Era of Highly Effective Direct-Acting Antiviral Agents. <b>2020</b> , 926-934		
58	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. <b>2020</b> , 50, 892-923		27
57	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <b>2021</b> , 51, 725-749		14
56	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <b>2021</b> , 56, 593-619		27
55	Liver Transplantation for Chronic Hepatitis B and C. 203-217		1
54	Management of HBV Infection and Liver Transplantation. <b>2010</b> , 748-761		1

53	Chronic Viral Hepatitis. <b>2010</b> , 1593-1617		1
52	Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling hepatitis B virus infection before and after transplantation. <b>2000</b> , 15, E172-E174		3
51	Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. <b>2000</b> , 15 Suppl, E181-6		18
50	Fulminant hepatitis B in patients with chronic HBV infection. <b>2000</b> , 15 Suppl, E178-80		1
49	Pre- and post-transplant treatment of hepatitis C. <b>2000</b> , 15 Suppl, E187-93		2
48	Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. <i>Transplantation</i> , <b>1999</b> , 68, 1912-4	1.8	96
47	Lamivudine for hepatitis B in liver transplantation: a single-center experience. <i>Transplantation</i> , <b>2000</b> , 69, 1403-7	1.8	68
46	Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. <i>Transplantation</i> , <b>2001</b> , 72, 1381-5	1.8	59
45	Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. <i>Journal of Clinical and Translational Hepatology</i> , <b>2016</b> , 4, 54-65	5.2	19
44	Guidelines for the management of hepatitis B virus infection. <i>Acta Hepatologica Japonica</i> , <b>2013</b> , 54, 402-472		3
43	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2012</b> , 18, 109-62	6.9	129
42	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 1706-12	5.6	15
41	Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2468-75	5.6	13
40	Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 14142-55	5.6	15
39	Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 584-92	5.6	16
38	Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 10290-8	5.6	8
37	Management of hepatitis B virus infection after liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 12083-90	5.6	12
36	Prophylactic managements of hepatitis B viral infection in liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 165-75	5.6	11



35	Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 2166-2176	5.6	3
34	Liver transplantation in the UK. <i>World Journal of Gastroenterology</i> , <b>2001</b> , 7, 602-11	5.6	26
33	Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 352-370	3.4	26
32	Liver transplantation in adults: Choosing the appropriate timing. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , <b>2012</b> , 3, 49-61	3	7
31	Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 168-176	1.8	8
30	Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 638-645	1.8	17
29	Prevalence of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2013</b> , 14, 5489-94	1.7	4
28	HBV/HDV management after liver transplantation: Review. <i>Journal of Liver Transplantation</i> , <b>2021</b> , 4, 100046		1
27	LAMIVUDINE MONOTHERAPY BEFORE AND AFTER LIVER TRANSPLANTATION IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. <i>Evidence-Based Gastroenterology</i> , <b>2001</b> , 2, 85-87		
26	Strategies for the Treatment of Hepatitis B and C After Liver Transplantation. <b>2002</b> , 48-61		
25	Prophylaxis and Posttransplant Treatment of Viral Hepatitis in Living-Donor Liver Transplantation. <b>2002</b> , 62-71		1
24	Viral Hepatitis in the Compromised Host. <b>2002</b> , 335-360		
23	Die neue Leber. <b>2002</b> , 54-58		
22	Lamivudine for chronic hepatitis B: Efficacy, safety, resistance, and current treatment issues. <b>2003</b> , 365-381		
21	Indications and General Pathology of Liver Transplantation Candidates. <i>Medical Radiology</i> , <b>2003</b> , 71-82	0.2	
20	Liver Transplantation. <b>2004</b> , 303-315		
19	Lamivudine Resistance-Associated Gene Mutations. <b>2004</b> , 700-702		
18	Late Complications of Liver Transplantation and Recurrence of Disease. <b>2005</b> , 995-1017		

17	Transplantation for Viral Hepatitis A and B. <b>2005</b> , 115-128		
16	Management of Recurrent Viral Hepatitis B and C. <b>2006</b> , 975-993		
15	Liver Transplantation. <b>2008</b> , 1787-1825		
14	Hepatitis B and Liver Transplantation. <b>2009</b> , 145-167		
13	Simple nucleos(t)ides as HBV prophylaxis regime of post-liver transplantation: Six-year followed up. <i>World Journal of Hepatology</i> , <b>2010</b> , 2, 447-50	3-4	
12	Viral Hepatitis and Transplantation. 88-96		
11	Prevention and Treatment of Recurrent HBV and HCV Infection. 361-371		
10	Liver transplantation. <i>Current Opinion in Gastroenterology</i> , <b>1999</b> , 15, 278-82	3	0
9	Hepatitis B Recurrence: Major Milestones and Current Status. <b>2016</b> , 13-34		
8	Organ Transplantation in HBV-Infected Patients. <i>Molecular and Translational Medicine</i> , <b>2016</b> , 361-397	0.4	
7	Prophylaxis Among Hepatitis B Core Antibody-positive Deceased-donor Liver Transplant Recipients: Hepatitis B Immunoglobulin Plus Oral Antiviral Agents Versus Antiviral Agents Alone: A Single-center Experience. <i>Experimental and Clinical Transplantation</i> , <b>2017</b> , 15, 183-188	0.8	2
6	Recurrent Primary Disease After Liver Transplantation. <b>2018</b> , 784-815.e14		
5	Prevention of HBV Recurrence after Liver Transplant: A Review. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 150-160	5.2	4
4	Hepatitis B virus infection in liver transplant candidates and recipients. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 20		
3	Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2014</b> , 7, 4057-66	1.4	7
2	Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
1	Low-Dose Hepatitis B Immune Globulin and Higher-Dose Lamivudine Combination to Prevent Hepatitis B Virus Recurrence after Liver Transplantation. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 921-927	1.6	21